Published in Clin Cancer Res on June 01, 2007
Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52
Current concepts of metastasis in melanoma. Expert Rev Dermatol (2008) 1.34
Positive nonsentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol (2008) 1.05
Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol (2011) 1.01
IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol (2011) 0.94
Inflammation and tumor microenvironment in lymph node metastasis. Cancers (Basel) (2011) 0.85
Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. Oncoimmunology (2015) 0.82
Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma. Medicine (Baltimore) (2016) 0.79
Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. Melanoma Res (2014) 0.78
Sentinel node and mechanism of lymphatic metastasis. Ann Vasc Dis (2012) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 3.36
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81
Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78
Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77
FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
Role of nuclear medicine in the management of cutaneous malignant melanoma. J Nucl Med (2006) 1.69
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.65
Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol (2006) 1.64
Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer: Practice Patterns and Short-term Outcomes Among 7061 Patients. Ann Surg (2015) 1.55
Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55
Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52
Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52
Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia (2010) 1.48
Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol (2004) 1.44
Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 1.43
Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol (2002) 1.42
Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41
Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.39
Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (2004) 1.32
Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg (2007) 1.32
Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31
Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol (2011) 1.29
Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg (2006) 1.28
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol (2013) 1.27
Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol (2006) 1.26
Hylan versus corticosteroid versus placebo for treatment of basal joint arthritis: a prospective, randomized, double-blinded clinical trial. J Hand Surg Am (2008) 1.25
Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol (2009) 1.25
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res (2009) 1.24
Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res (2003) 1.24
Noninvasive, quantitative assessment of left ventricular function in ischemic cardiomyopathy. J Surg Res (2004) 1.24
Lymphatic mapping and sentinel node analysis: current concepts and applications. CA Cancer J Clin (2006) 1.24
Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer (2005) 1.23
Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23
Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol (2009) 1.22
The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med (2003) 1.21
Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol (2004) 1.20
Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol (2007) 1.19
Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res (2007) 1.19
Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol (2009) 1.18
Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol (2003) 1.18
Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg (2013) 1.18
Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res (2006) 1.18
Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17
The role of surgery in treatment of stage IV melanoma. J Surg Oncol (2006) 1.17
Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg (2004) 1.16
Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg (2005) 1.15
Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol (2007) 1.14
B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg (2010) 1.13
Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol (2005) 1.12
Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res (2005) 1.11
The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg (2002) 1.11
Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev (2006) 1.11
Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10